A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease
Phase of Trial: Phase II
Latest Information Update: 18 Jan 2017
At a glance
- Drugs Selonsertib (Primary)
- Indications Diabetic nephropathies
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 20 Oct 2016 According to Gilead Sciences media release, Data from this study will be submitted for presentation at upcoming scientific conference.
- 20 Oct 2016 Primary endpoint has not been met.
- 30 Aug 2016 Status changed from active, no longer recruiting to completed.